Key Takeaways for Haemonetics Corporation Stock as of August 2026
- CSL Plasma Deal: Haemonetics (HAE) stock jumped 15.93% on Tuesday, August 18, closing at $104.65, up $14.38, after the company disclosed a non-exclusive US supply agreement with CSL Plasma for its NexSys PCS devices.
- Target Flip: The Street’s 10-analyst mean target sits at $100, now 4% below the $105 close, the first time in more than a year that Haemonetics stock has traded above where analysts peg it.
- Model Gap: TIKR’s mid-case valuation model puts fair value at $93 against the current $105 price, implying a -10.8% total return and a -2.4% annualized return through a realization date of March 2031.
- Same-Day Upgrades: BofA Global Research raised its price objective to $120 from $100 and BTIG lifted its target to $110 from $96, both citing the CSL Plasma news within hours of the disclosure.
Haemonetics stock just closed the gap the Street had been pricing in for a year, and now the question is whether it closed too much of it. See how the TIKR valuation model prices HAE stock today on TIKR for free →
Why Haemonetics Stock Jumped 16% on the CSL Plasma Supply Deal
Haemonetics Corporation (HAE) stock surged 15.93% on Tuesday, August 18, closing at $104.65 after the company disclosed a non-exclusive commercial supply agreement with CSL Plasma, one of the largest plasma collectors in the United States. The agreement, signed August 14 and revealed publicly four days later, lets CSL Plasma adopt Haemonetics’ NexSys PCS devices equipped with Persona PLUS technology across its US collection centers and purchase the related single-use disposables.
That single word, disposables, is the reason the market reacted the way it did. Haemonetics runs a razor-and-blade model in plasma: once a center installs the NexSys hardware, every collection afterward pulls through a recurring disposable sale. CSL Plasma is a company that did not run Haemonetics devices at scale before this agreement, so the deal opens a large new pool of centers to that recurring revenue stream, at least in theory.
The catch sits in the fine print. Haemonetics confirmed the arrangement carries no minimum purchase commitments, and the company said the precise scope and implementation schedule remain undetermined. Fiscal 2027 guidance stayed unchanged on the news, and management said it will address the financial impact on the second-quarter earnings call in November. Investors bought the option value of the relationship first and asked for the numbers later.
CEO Chris Simon previewed exactly this kind of expansion two weeks earlier on the August 6 first-quarter call, when he described Persona PLUS as “a relatively straightforward software upgrade” that lets the company convert “30 or 40 centers a week without any kind of reluctance.” He added that the company could “conceptually and without much to do, convert the entire US market this year,” but stressed that guidance only reflects contracts with a committed timeline. The CSL Plasma agreement is the first sign that conversion pipeline extends beyond Haemonetics’ existing customer base and into a competitor’s installed footprint.
That reframes the thesis. This was never purely an earnings story. It is a distribution story, and the CSL Plasma name attached to it is what pulled the stock through its own price ceiling in a single session.
Sell-side price targets on Haemonetics stock also require checking. TIKR gives you free access to the same Street-following data serious investors use before they chase a 16% gap up. Track HAE stock price targets on TIKR for free →
Haemonetics Stock’s Mean Target Falls Behind the Price for the First Time
The current Street snapshot on Haemonetics stock shows 4 buys, 4 outperforms and 3 holds among 10 covering analysts, with no underperform or sell ratings on the books.
The mean target sits at $100.30 against Tuesday’s $104.65 close, a gap that works out to roughly 4% below the current price rather than above it.
That inversion is new. Go back across the last five quarterly snapshots and the mean target sat comfortably above the close every single time: 123% of price in June 2025, 163% in September, 114% in December, 162% in March 2026, and 110% in June. Coverage held steady near 10 to 11 analysts through that stretch even as the stock swung from $48 to $104. Analysts were consistently more bullish than the tape, sometimes by more than 50 points of implied upside.
Tuesday flipped that relationship. The stock’s 16% jump outran the Street’s own mean by enough to put Haemonetics stock on the wrong side of consensus for the first time in over a year, even as individual analysts scrambled to catch up. BofA’s move to $120 and BTIG’s move to $110, both same-day, pulled the high end of the range up to $120 from a prior $108 high. But the mean has not caught the price yet, and that lag is the story the table tells.
TIKR Values HAE Stock at $93, Below Where the CSL Plasma Pop Left It
TIKR’s mid-case model values Haemonetics at $93 by a realization date of March 2031, implying a -10.8% total return from the current price of $105, or -2.4% annualized over 4.6 years.
A negative annualized return on a stock that just posted its best single session in years puts Haemonetics in rare company among names that rallied on deal news this week, and it says the model treats Tuesday’s move as a repricing of optionality rather than of cash flow already in hand.
The gap traces directly back to Section 1 and Section 2. CSL Plasma carries no minimum volume commitment and no disclosed timeline, so the revenue behind the 16% move has not shown up in a guidance figure yet, and the Street’s own $100 mean target already sits below where the stock landed.
The model is not arguing the CSL Plasma relationship lacks value. It is arguing the market paid for the full relationship in one afternoon before Haemonetics confirmed how much of it will actually convert to disposable sales.
Should You Invest in Haemonetics Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Haemonetics Corporation stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Haemonetics Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze HAE stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
